The largest scientific study ever conducted in Iceland

In the first month of the study, more than 50,000 Icelanders signed up to participate.

Registration for the study ends, with a total of 80,759 registrations, which is equivalent to a 54% participation rate, a unique achievement worldwide.

The Promotional Campaign for iStopMM gets an award from The Icelandic Association of Marketers.

First participants starts iStopMM treatment trial.

The first scientific article published in the Blood Cancer Journal. In this first paper from the iStopMM trial, the methodology and the recruitment phase of the study was described in detail. The paper introduces the study to the scientific community and shows that the particiation rate is high enabling the study to reach its goals.

iStopMM presents four oral abstracts and two posters at the American Society of Hematology (ASH) Annual Meeting in Atlanta.

Many of the planned studies from the iStopMM project use data on chronic disease diagnoses in the Icelandic healthcare registries. In this paper the accuracy of these diagnoses was assessed. The accuracy varied somewhat between diseases but the overall accuracy was estimated at 98.5% which is very high.

An article based on iStopMM data shows that previous reference intervals for serum free light chains (FLC) and the FLC ratio are inaccurate in individuals with kidney disease. The paper proposes new reference intervals for FLC and FLC ratio based on kidney function that changes the definition of light chain MGUS in individuals with kidney disease.